Deregulated mTOR-mediated translation in intellectual disability.

Prog Neurobiol

Departamento de Fisiología Médica y Biofísica, Universidad de Sevilla, Av. Sánchez-Pizjuán 4, E-41009 Sevilla, Spain.

Published: February 2012

AI Article Synopsis

  • Local translation of dendritic mRNAs is vital for the development of dendrites and synaptic plasticity, which are often disrupted in intellectual disabilities.
  • The mTOR protein kinase plays a key role in these processes and is hyperactivated in some mouse models of intellectual disabilities like Fragile X and tuberous sclerosis, leading to increased local dendritic translation.
  • Inhibition of mTOR with rapamycin has shown promise in normalizing translation rates and improving behavior and synaptic function in these models, indicating potential therapeutic benefits for various cognitive impairments.

Article Abstract

Local translation of dendritic mRNAs is a key aspect of dendrite and spine morphogenesis and synaptic plasticity, two phenomena generally compromised in intellectual disability disorders. Mammalian target of rapamycin (mTOR) is a protein kinase involved in a plethora of functions including dendritogenesis, plasticity and the regulation of local translation. Hence, this kinase may well be implicated in intellectual disability. Hyperactivation of mTOR has been recently reported in mouse models of Fragile X and tuberous sclerosis, two important causes of intellectual disability. Moreover, local dendritic translation seems to be increased in Fragile X syndrome. Recent findings show that the mTOR pathway is also deregulated in murine models of Rett's syndrome and Down's syndrome. As in Fragile X, local dendritic translation seems to be abnormally active in Down's syndrome mice, while rapamycin, a Food and Drug Administration-approved mTOR inhibitor, restores normal rates of translation. Rapamycin administration in tuberous sclerosis mice rescues deficits in behavior and synaptic plasticity. Indeed, mTOR-dependent deregulation of local translation may be a common trait in different intellectual deficiencies, suggesting that mTOR inhibitors may have significant therapeutic potential for the treatment of diverse forms of cognitive impairment.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pneurobio.2012.01.005DOI Listing

Publication Analysis

Top Keywords

intellectual disability
16
local translation
12
disability local
8
synaptic plasticity
8
tuberous sclerosis
8
local dendritic
8
dendritic translation
8
down's syndrome
8
translation
7
intellectual
5

Similar Publications

The tRNA methyltransferase 1 (TRMT1) enzyme catalyzes the N2,N2-dimethylguanosine (m2,2G) modification in tRNAs. Intriguingly, vertebrates encode an additional tRNA methyltransferase 1-like (TRMT1L) paralog. Here, we use a comprehensive tRNA sequencing approach to decipher targets of human TRMT1 and TRMT1L.

View Article and Find Full Text PDF

The Genetics of Neurodevelopmental Disorders Lab in Padua provided a new intellectual disability (ID) Panel challenge for computational methods to predict patient phenotypes and their causal variants in the context of the Critical Assessment of the Genome Interpretation, 6th edition (CAGI6). Eight research teams submitted a total of 30 models to predict phenotypes based on the sequences of 74 genes (VCF format) in 415 pediatric patients affected by Neurodevelopmental Disorders (NDDs). NDDs are clinically and genetically heterogeneous conditions, with onset in infant age.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Fleni, Buenos Aires, Argentina.

Background: Down Syndrome (DS) is the most common genetic form of intellectual disability. In recent years, there has been a significant increase in the life expectancy of individuals with DS, currently reaching the age of 60 or over. However, it has been observed that as of age 40, these individuals experience higher risk of developing dementia, and almost all of them exhibit histopathological characteristics of Alzheimer's disease (AD) in their brains.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

University of Wisconsin-Madison, Madison, WI, USA.

Background: People with Down syndrome (DS) are genetically at-risk for Alzheimer's disease (AD). The age of symptomatic AD in DS varies (late-40s-70s). Lifestyle factors are theorized to explain some of this variability.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA; NYU Langone Health, New York, NY, USA.

Background: Clinical and preclinical evidence suggest that abnormal electrical activity strongly impacts outcomes in Alzheimer's disease (AD). Indeed, AD patients with interictal spikes (IIS) show faster cognitive decline than those without IIS. Furthermore, seizures in patients with AD have been suggested to accelerate disease progression.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!